NantKwest to Present at Upcoming Investment and Healthcare Conferences
March 13 2018 - 7:29PM
Business Wire
NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer
cell-based therapeutics company, today announced that the company
will be presenting and conducting one-on-one meetings at a number
of investment and healthcare conferences in the month of March and
April 2018. The presentations and one-on-one discussions will
feature a science and business overview, along with a clinical
update provided by company management.
Conference Details:
Event: Roth
Capital 30th Annual Investment Conference Date/Time: Tuesday, March
13, 2018, one-on-one meetings Location: Laguna Niguel, CA
Event: Cowen & Company 38th Annual Healthcare Conference
Date/Time: Wednesday, March 14, 2018, one-on-one meetings Location:
Boston, MA Event: Oppenheimer & Company 28th Annual
Healthcare Conference Date/Time: Tuesday, March 20, 2018,
one-on-one meetings Location: New York, NY Event: Needham
& Company 17th Annual Healthcare Conference Date/Time:
Wednesday, March 28, 2018, presentation at 12:45pm Location: New
York, NY Event: Hanson Wade Innate Killer Summit Date/Time:
Thursday, March 29, 2018, presentation at 12:50pm Location: New
York, NY Event: Jefferies IO Cell Therapy Investment
Conference Date/Time: Tuesday, April 3, 2018, presentation at
11:40am Location: Boston, MA
About NantKwest Inc.
NantKwest (Nasdaq:NK) is a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of our immune system using natural killer (NK) cells
to treat cancer, infectious diseases and inflammatory diseases. NK
cells are the body’s first line of defense due to the innate
ability of NK cells to rapidly identify and destroy cells under
stress, such as cancer or virally-infected cells.
NantKwest’s unique NK cell-based platform, with the capacity to
grow active killer cells as a biological cancer therapy, has been
designed to induce cell death against cancer or infected cells by
three different modes of action: (1) Direct killing using activated
NK cells (aNK) that release toxic granules directly into the cell
through cell to cell contact; (2) Antibody-mediated killing using
haNKs, which are NK cells engineered to incorporate a high affinity
receptor that binds to an administered antibody, enhancing the
cancer cell killing effect of that antibody; and (3) Targeted
activated killing using taNKs, which are NK cells engineered to
incorporate chimeric antigen receptors (CARs) to target
tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of
T cell therapies, including the reduction of risk of serious
“cytokine storms” reported after T cell therapy. As an
“off-the-shelf” therapy, NantKwest's NK cells do not rely on a
patient’s own, often compromised immune system. In Phase 1 clinical
trials in patients with late stage cancer, NantKwest’s NK cells
have been successfully administered as an outpatient infusion
therapy without any reported severe side effects, even at doses of
10 billion cells.
By leveraging an integrated and extensive genomics and
transcriptomics discovery and development engine, together with a
pipeline of multiple, clinical-stage, immuno-oncology programs that
include a Phase 2 trial for a rare form of melanoma and the planned
initiation of a clinical trial of NK cells targeted to breast
cancer, we believe NantKwest is uniquely positioned to be the
premier immunotherapy company and transform medicine by delivering
living drugs in a bag and bringing novel NK cell-based therapies to
routine clinical care. For more information please visit
www.nantkwest.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180313006588/en/
Media Contact:NantKwestJen
Hodsonjhodson@nantworks.com
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Apr 2023 to Apr 2024